Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Trial Profile

Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs GL ONC1 (Primary)
  • Indications Carcinoma; Malignant pleural effusion; Mesothelioma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Jan 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
    • 17 Jan 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top